Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | MRD-negativity rates in the IKEMA trial of isa plus kD in R/R myeloma

Philippe Moreau, MD, Nantes University Hospital, Nantes, France, discusses the findings of an analysis of response depth and kinetics in the Phase III IKEMA study of carfilzomib (K) and dexamethasone (d) with or without isatuximab (isa) in relapsed/refractory (R/R) multiple myeloma. A deeper response, indicated by measurable residual disease (MRD) negativity, is related to improved survival outcomes. Therefore, MRD assessment of bone marrow aspirates was conducted by next generation sequencing on all trial participants who achieved very good partial response or better. The results found a significantly higher proportion of patients reached MRD-negativity in the Isa-Kd arm, compared to the Kd arm, fitting with the deeper responses seen with Isa-Kd use. MRD-negative patients showed a prolonged progression free survival compared to those who were MRD-positive in both trial arms. This interim analysis highlights the clinical benefits of Isa-Kd use with regards to the depth of response.